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Abstract
Background:  CD4+ T lymphocyte (CD4) cell count testing is the standard method for
determining eligibility for antiretroviral therapy (ART), but is not widely available in sub-Saharan
Africa. Total lymphocyte counts (TLCs) have not proven sufficiently accurate in identifying subjects
with low CD4 counts. We developed clinical algorithms using TLCs, hemoglobin (Hb), and body
mass index (BMI) to identify patients who require ART.
Methods: We conducted a cross-sectional study of HIV-infected adults in Uganda, who presented
for assessment for ART-eligibility with WHO clinical stages I, II or III. Two by two tables were
constructed to examine TLC thresholds, which maximized sensitivity for CD4 cell counts ≤ 200
cells µL, while minimizing the number offered ART with counts > 350 cells µL. Hb and BMI values
were then examined to try to improve model performance.
Results: 1787 subjects were available for analysis. Median CD4 cell counts and TLCs, were 239
cells/µL and 1830 cells/µL, respectively. Offering ART to all subjects with a TLCs ≤ 2250 cells/µL
produced a sensitivity of 0.88 and a false positive ratio of 0.21. Algorithms that treated all patients
with a TLC <2000 cells/µL, excluded all patients with a TLC >3000 cells/µL, and used Hb and/or
BMI values to determine eligibility for those with TLC values between 2000 and 3000 cells/µL,
marginally improved accuracy.
Conclusion: TLCs appear useful in predicting who would be eligible for ART based on CD4 cell
count criteria. Hb and BMI values may be useful in prioritizing patients for ART, but did not improve
model accuracy.
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Background
Guidelines developed by the World Health Organization
(WHO) for the use of antiretroviral therapy (ART) in low-
income countries state that HIV-infected individuals
should commence ART if they have WHO stage IV disease,
stage III disease and a CD4+ T lymphocyte (CD4) cell
count of ≤350 cells/µL, or stage I or II disease with CD4
cell counts ≤200 cells/µL [1]. Recently WHO has recom-
mended to increase this threshold for stage I and II indi-
viduals to 350 cells/µL [2].
If CD4 cell counting is not available, as is the case in most
of sub-Saharan Africa, the WHO guidelines recommend
using clinical staging alone, or in combination with total
lymphocyte counts (TLCs) of < 1200/µL in order to deter-
mine ART eligibility[1]. However, many studies have
found both clinical stages III/IV and this TLC threshold to
have poor sensitivity for low CD4 cell counts, leading
researchers attempt to define other TLC thresholds which
better correspond to CD4 cell counts ≤ 200 or 350 cells/
µL [3-5]. Studies which have incorporated hemoglobin
(Hb) or hematocrit into clinical algorithms have shown
improved performance of TLC in predicting low CD4 cell
counts[6-8]. However, such studies have treated the CD4
cell count threshold as an absolute standard, where initi-
ating treatment in patients with cell counts above 200
cells/µL is undesirable. As delaying ART until CD4 cell
counts fall below 200 cells/µL results in increased mortal-
ity[9] and most studies from sub-Saharan African settings
have shown high mortality rates in the first year on ther-
apy [10-12], it seems reasonable to adopt the more liberal
ART eligibility criteria of <350 cells/µL.
We designed an analysis among HIV-infected adults in
rural Uganda being screened for ART eligibility. We exam-
ined the clinical utility of TLCs, Hb, and body mass index
(BMI) to maximize the sensitivity to detect individuals
with CD4 cell counts below 200 cells/µL, and limit the
proportion of individuals who would be offered ART with
CD4 cell counts above 350 cells/µL.
Methods
The Home-Based AIDS Care Program (HBAC) is a clinical
trial of three different monitoring strategies for patients
receiving ART in rural Eastern Uganda. Registered clients
of The AIDS Support Organization (TASO), a local HIV/
AIDS care and support organization in Tororo and Busia
districts, were invited to be screened for ART eligibility.
The study includes participants from a prior diarrhea pre-
vention and cotrimoxazole study described elsewhere
[13], as well as newly recruited clients. Aggregated data
from screening at baseline were used for this analysis. The
studies were approved by the Science and Ethics Commit-
tee of the Uganda Virus Research Institute and the Institu-
tional Review Boards of the Centers for Disease Control
and Prevention and the University of California, San Fran-
cisco.
All subjects in this analysis were HIV-infected adults aged
≥ 18 years. Clinical and laboratory assessments at baseline
included a complete blood counts (CBC), viral load, and
CD4 cell counts. Those who had a CD4 count ≤250 or had
WHO stage III (excluding pulmonary TB) or IV were
offered ART. Blood samples for TLC and CD4 testing were
collected in the same vacutainer tube containing EDTA at
the study clinic and transported to the CDC laboratory in
Entebbe. CD4 cell counts were measured by a dual-plat-
form protocol using a FACScan instrument and Tritest rea-
gents (Beckson-Dickenson, San Carlos, CA). TLCs were
measured both using a hematology analyzer (Beckman-
Coulter, Fullerton, CA) and the FACScan instrument. We
have previously found that delays in transport of up to 5
days do not affect the accuracy of the FACScan results for
CD4 cell counts (R. Downing, unpublished data) and
therefore used the TLC results obtained on the FACScan in
order to determine if transport time to the lab significantly
affected the difference between the two methods. TLCs
results from the hematology analyzer were used for the
analysis. Clinical information during screening was col-
lected using standardized instruments completed by study
physicians. Subjects with WHO stage IV disease were
excluded for this analysis.
Bivariate correlations between TLC results obtained on
the FACscan and hematology analyzer were conducted.
Differences between the two results were calculated and
compared with results stratified by time between blood
draw to testing of ≤ 1 day and > 1 day, using the Wilcoxan
Rank Sum test. Distributions of TLCs, Hb and BMI across
CD4 cell count strata were compared in a pair-wise fash-
ion using the Wilcoxan Rank Sum test. Two by two tables
were constructed to examine the association between dif-
ferent strata of TLCs, Hb and BMI with CD4 cell counts ≤
200/µL or ≤350/µL. Sensitivity, specificity, positive and
negative predictive values and accuracy (true positives +
true negatives/all subjects) of the models were then calcu-
lated. We examined different TLC thresholds in terms of
their ability to maximize sensitivity in detecting subjects
with CD4 cell counts ≤ 200 cells/µL and minimize the
proportion of subjects offered ART with cell counts > 350
cells/µL (false positives). Hb and BMI thresholds, alone
and in combination, were then used to classify subjects
with intermediate TLCs as qualifying for therapy. 95%
confidence intervals for sensitivity and false positive ratios
were calculated for the final models according to the Wald
method [14]. Final models were then run under the sce-
nario where all subjects with WHO stage III disease were
offered ART and the algorithm was used to determine ART
eligibility for those with stages I and II only. Final models
were also examined separately for men and women.AIDS Research and Therapy 2007, 4:1 http://www.aidsrestherapy.com/content/4/1/1
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The effects of tuberculosis, malaria parasitemia, or
diarrhea at the time of screening were examined by con-
ducting sub-group analyses which excluded subjects with
these illnesses. All statistical analyses were conducted in
SAS version 9.0 (SAS Institute, Cary, NC)
Results
Between May 2003 and June 2005, 1944 HIV-infected
adults presented for assessment of ART eligibility. Of
these, 104 (5.2%) were excluded from this analysis as they
were found to have WHO clinical stage IV disease.
Another 53 individuals were excluded because of missing
TLC or CD4 cell count values leaving 1787 subjects avail-
able for analysis. 75.2% were women and 27.8% were
men. Median baseline CD4 cell counts and total lym-
phocyte counts, were 239 (inter-quartile range [IQR] =
119–411) and 1830 (IQR = 1420–2360) cells/µL, respec-
tively. The mean time between blood sample collection
and TLC and CD4 testing was 1.4 days; 56% of subjects
had blood tested on the same day or one day after blood
draw and 43% were tested 2 days after blood draw. One
patient had blood tested 8 days after blood draw and was
excluded from the analysis. TLC results between the
hematology analyzer and the FACScan instrument were
highly correlated (Pearson's r2 = 0.85, p < 0.001) with the
analyzer consistently giving greater values (median differ-
ence 383 cells/µL; IQR = 253 – 560). Differences were
slightly greater for subjects whose blood samples were
tested 2 days after blood draw in comparison with those
whose blood was tested ≤ 1 day after draw (399 cells/µL
vs. 360 cells/µL, p = 0.003).
In total, 763 (42.7%) subjects had baseline CD4 cell
counts  ≤ 200 cells/µL, 459(25.7%) had cell counts of
201–350 cells/µL and 565 (31.6%) had CD4 counts > 350
cells/µL (Table 1). Median baseline hemoglobin was 11.6
g/Dl (IQR = 10.3–12.8) and median baseline body mass
index was 20.0 kg/m2 (IQR = 18.-21.9). TLCs, Hb and BMI
were distributed differently between the CD4 cell count
strata (p < 0.01, for pair-wise comparisons for all parame-
ters), with higher values for all parameters measured in
the higher CD4 cell count strata.
A TLC threshold of 2250 cells/µL was the most accurate
(0.73) predictor of CD4 cell counts ≤ 350 cells/µL, yield-
ing a sensitivity of 0.81 and a specificity of 0.54 (Table 2).
This corresponded to a sensitivity of 0.88 (95% confi-
dence interval [CI] 0.86 – 0.90) for CD4 cell counts ≤ 200
cells/µL and would result in 21% (95% CI 0.18 – 0.24) of
subjects being offered ART with CD4 cell counts > 350
cells/µL (false positives). Incorporating Hb and/or BMI
into algorithms produced two models with accuracy levels
of 0.75. Both methods would offer ART to all subjects
with TLCs ≤ 2000 cells/µL and defer treatment for those
with TLCs > 3000 cells/µL. To evaluate subjects with TLCs
between 2000 and 3000 cells/µL, the first model used Hb
≤ 11 g/Dl alone and had a sensitivity of 0.88 (95% CI 0.86
– 0.90) for CD4 cell counts ≤ 200 cells/µL and a false pos-
itive ratio of 0.18 (95% CI 0.15 – 0.21). The second model
used Hb values ≤ 11 g/Dl or a BMI ≤ 18 kg/m2 to classify
intermediate TLCs and resulted in a sensitivity of 0.90
(95% CI 0.88 – 0.92) and a false positive ratio of 0.20
(95% CI 0.17 – 0.23). Figure 1 describes the flow of
patients through the second algorithm. The use of these
algorithms would have resulted in treatment being
offered to 1212 and 1268 subjects, respectively, in com-
parison to 1230 subjects, if all subjects with CD4 cell
counts ≤ 350 cells/µL were offered treatment.
Results for women were unchanged from that of the
whole group (data not shown). Both algorithms from the
whole group analysis performed well for men separately,
with accuracies of 0.72 and 0.73 for the models including
TLC and Hb; and TLC, Hb and BMI, respectively (Table
2E). However, the highest accuracy was found using an
algorithm with TLC thresholds of 2000 and 3000, to
firstly include and exclude subjects for treatment; and Hb
values of 12 g/dL and BMI of 18 kg/m2 to assign treatment
to those with intermediate TLCs. This model had an accu-
racy of 0.75, a sensitivity for CD4 cell counts ≤ 200 cells/
µL of 0.87 and a false positive ratio of 0.14.
Offering ART to all subjects with WHO stage III disease
and using the algorithms to determine ART-eligibility for
those with stage I or II disease would have resulted in
treatment being offered to 1282 or 1328 subjects with
similar levels of sensitivity and false positives. A total of
19 subjects had malaria parasitemia, 60 subjects were on
TB treatment or diagnosed with TB at screening and 96
subjects had diarrhea at screening. However, excluding
any of these subjects did not improve the predictive value
of the final models.
Discussion
We have demonstrated that using a TLC of 2250 cells/µL
to determine ART eligibility in subjects with WHO clinical
stages I, II or III, could identify 88% of subjects with CD4
cell counts ≤ 200 cells/µL, while 21% of subjects offered
ART would have CD4 cell counts > 350 cells/µL. Using a
TLC threshold of 2000 cells/µL to offer ART and an upper
threshold of 3000 cells/µL to exclude subjects from treat-
ment with Hb and BMI thresholds to determine ART eligi-
bility for those with intermediate TLCs only marginally
improved the accuracy of TLCs alone.
Despite the failure to improve accuracy of TLCs in predict-
ing CD4 cell counts, using Hb and BMI may still be of
value in determining who should initiate ART in resource-
limited settings. Recent studies have shown that low Hb
values and low BMI are independent risk factors for earlyAIDS Research and Therapy 2007, 4:1 http://www.aidsrestherapy.com/content/4/1/1
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mortality on ART in African settings [15,16]. Therefore
Table 1: Distribution of total lymphocyte counts, hemoglobin and body mass index values by CD4 strata for 1787 HIV – infected 
subjects in Tororo, Uganda.
CD4 cell count 
≤ 200 cells/µL
(column 1)
P value 
(column 1 to 2)
CD4 cell count 
200 – 350 cells/µL
(column 2)
P value
(column 2 to 3)
CD4 cell count > 
350 cells/µL
(column 3)
Number of subjects (%) 763 (42.7) 459 (25.7) 565(31.6)
TLC – cells/µL median 
(interquartile range)
1460 (1120 – 
1910)
<0.001 1880 (1570 – 2330) <0.001 2330 (1910 – 2860)
Hb in g/dL median (IQR) 11.3 (10.0 – 12.4) <0.001 11.8 (10.6 – 12.9) <0.001 12.3 (11.4 – 13.2)
BMI in kg/m2 median (IQR) 19.7 (18.0 – 21.5) <0.001 20.4 (18.9 – 21.9) 0.009 20.8 (19.2 – 22.8)
Table 2: Performance of algorithms using TLCs alone or in combination with Hb and BMI in predicting CD4 cell counts ≤ 350 cells/µL 
in the Home-Based AIDS Care project, Tororo, Uganda
TLC Lower 
threshold
TLC 
Upper 
threshold
Hb 
threshold
BMI 
threshold
Sensitivity 
for CD4 
<350
Specificity 
for CD4 
<350
accuracy sensitivity 
for 
CD4<200
False 
Positives
N Qualifying 
For ART
A) CD4 alone 1.00 1.00 1.00 1.00 0 1230
B) TLC alone
1500 0.40 0.95 0.67 519
1750 0.59 0.85 0.67 0.69 0.11 801
2000 0.71 0.69 0.71 0.80 0.17 1043
*2250 0.81 0.54 0.73 0.88 0.21 1250
2500 0.88 0.41 0.73 0.93 0.24 1404
2750 0.92 0.28 0.72 0.96 0.27 1523
3000 0.95 0.21 0.71 0.97 0.28 1601
C) TLC combined with Hb and/or BMI
1750 2750 11 0.71 0.75 0.68 0.81 0.14 1017
1750 2750 12 0.78 0.62 0.73 0.86 0.18 1180
1750 2750 18 0.64 0.77 0.68 0.75 0.14 917
1750 2750 11 18 0.74 0.69 0.73 0.84 0.16 1087
*2000 3000 11 0.81 0.62 0.75 0.88 0.18 1212
2000 3000 12 0.85 0.51 0.74 0.94 0.21 1335
2000 3000 18 0.75 0.63 0.72 0.84 0.19 1138
**2000 3000 11 18 0.83 0.57 0.75 0.90 0.20 1268
1750 2500 11 0.69 0.76 0.72 0.79 0.14 989
1750 2500 12 0.79 0.61 0.73 0.84 0.20 1169
1750 2500 11 18 0.72 0.72 0.72 0.82 0.15 1045
2000 2750 11 0.79 0.62 0.74 0.86 0.18 1190
2000 2750 18 0.75 0.64 0.71 0.83 0.19 1128
2000 2750 11 18 0.81 0.57 0.74 0.89 0.20 1242
D) TLC combined with Hb and/or BMI for WHO stages I and II only
**2000 3000 11 0.80 0.62 0.74 0.93 0.19 1282‡
2000 3000 11 18 0.83 0.57 0.73 0.90 0.20 1328‡
E) TLC combined with Hb and/or BMI for men only
2000 3000 11 0.58 0.71 0.72 0.80 0.12
2000 3000 12 0.76 0.63 0.73 0.84 0.14
2000 3000 11 18 0.77 0.60 0.73 0.87 0.14
**2000 3000 12 18 0.80 0.57 0.75 0.89 0.15
Models with the highest accuracy using TLC alone (*) and TLC and Hb +/- BMI (**)
‡ Includes offering ART to 333 subjects with WHO stage III disease of whom 46 had CD4 cell counts > 350 cells/µL.AIDS Research and Therapy 2007, 4:1 http://www.aidsrestherapy.com/content/4/1/1
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Algorithm for determining ART eligibility for 1787 HIV infected individuals using TLCs, Hb and BMI Figure 1
Algorithm for determining ART eligibility for 1787 HIV infected individuals using TLCs, Hb and BMI.
1944 adults 
 (≥ 18 yrs) present for 
assessment of ART 
eligibility 
184 with TLCs > 
3000 cells/ µL 
1787 subjects 
available for analysis 
53 subjects (2.7%) 
excluded b/c missing 
TLC or CD4 results 
109 (5.2%) excluded 
b/c WHO clinical stage 
IV disease 
558 subjects with TLCs 
2001 - 3000 cells/ µL 
1043 with TLCs ≤ 
2000 cells/ µL 
ART offered to all 
TLC result
ART decision 
unclear 
ART deferred for 
all 
Hb and BMI 
assessment 
341 with  
Hb > 11 g/dL 
and BMI > 18  
kg/m2 
216 with  
Hb ≤ 11 g/dL 
or BMI ≤ 18   
kg/m2 
 
ART offered   ART deferred 
868 
True 
positive 
CD4s ≤ 
350 
cells/ µL 
175 
False 
positive 
CD4s > 
350 
cells/ µL 
161 
True 
negative 
CD4s > 
200 
cells/ µL 
23  
False 
negative 
CD4s ≤ 
200 
cells/ µL 
144 
True 
positive 
CD4s ≤ 
350 
cells/ µL 
72  
False 
positive 
CD4s > 
350 
cells/ µL 
51  
False 
negative 
CD4s ≤ 
200 
cells/ µL 
290 
True 
negative 
CD4s > 
200 
cells/ µL AIDS Research and Therapy 2007, 4:1 http://www.aidsrestherapy.com/content/4/1/1
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incorporating Hb and BMI into ART eligibility criteria
may help to prioritize treatment for those who are at
increased risk of death if ART is delayed until CD4 cell
counts drop further. ART guidelines in use in industrial-
ized countries recommend treatment for individuals with
CD4 cell counts in the range of 200 – 350 cells/µL prima-
rily for those with factors which may limit the effective-
ness of ART if treatment is much delayed [17]. The strategy
proposed here adopts a similar approach but one which is
likely more relevant to HIV-infected individuals living in
sub-Saharan Africa.
The number of patients offered therapy under our TLC/
Hb/BMI criteria were similar to the number offered treat-
ment had ART been offered to all patients with CD4 cell
counts ≤ 350 cells/µL, however, the same patients would
not be treated under both scenarios. Between 17 and 19%
of subjects with CD4 cell counts ≤350 cells/µL would not
be offered ART using the TLC/Hb/BMI algorithms, how-
ever, as they would not have low BMIs or low Hb values,
unless they also had TLCs >3000 cells/µL, it is unlikely
that they would be at risk for early mortality without treat-
ment.
More than 75% of the participants in this study were
women. While the proportion of women aged 15 – 59
with HIV in Uganda is about 28% greater than men (7.3
versus 5.2%)[18], it is likely that differences in health
seeking behavior are a more likely explanation for the
large differences in the numbers of men and women seen
in our study. When models were run excluding women
from the analysis, we found that using a Hb threshold of
12 g/dL was a more accurate threshold for distinguishing
which men had low CD4 cell counts.
If TLCs are to prove to be a viable alternative to using CD4
cell counting in managing HIV-infected individuals in
resource-limited settings, they will need to be shown to be
useful not only in determining when individuals should
initiate ART, but also in monitoring patients on ART.
There have been few studies on the use of TLCs in moni-
toring individuals on ART, but all have concluded that
TLCs correlate well with changes in CD4 cell counts on
ART[19,20]. However, the most recent ART guidelines
from WHO state that "TLC is not suitable for monitoring
therapy as a change in the TLC value does not reliably pre-
dict treatment success."[2] It is unclear from where this
recommendation derives as no reference is provided.
The proportion of subjects in our study with CD4 cell
counts ≤ 200 cells/µL and ≤ 350 cells/µL was very high
(42.7% and 68.4%, respectively), resulting in a large
number of subjects being ART-eligible. It is likely that our
algorithm may not function as well in settings where the
proportion of ART eligible subjects is not so high. How-
ever, uptake of voluntary counseling and testing is quite
low in Uganda in that only 13% of women and 11% of
men have ever been tested for HIV[18] and is also likely
very low in other sub-Saharan African countries. Therefore
it is reasonable to expect that many people presenting for
assessment of ART-eligibility will have been tested for HIV
because of ill health and a large proportion will likely
meet eligibility criteria.
This study has two potential limitations. Firstly, TLCs and
CD4 cell counts were not conducted at the site of blood
drawing, but were transported to the CDC laboratory in
Entebbe, which may have resulted in some deterioration
of the blood samples. However, we had previously shown
that CD4 cell count results from the FACScan instrument
are stable up to 5 days after blood draw and the variability
between the TLC values obtained on the FACScan were
only a median of 40 cells/µL less for subjects whose blood
was tested 2 days after draw compared to those whose
samples were tested after ≤ 1 day delay between blood col-
lection and testing. These observations suggest that trans-
port time may not have caused significant inaccuracy in
our laboratory test results. Secondly, the gold standard for
determining inclusion or exclusion criteria for ART used
in this study, that of CD4+ T lymphocyte counts, are also
not perfect predictors of morbidity and mortality among
people with HIV. While CD4 cell counting has proven
useful in allowing stratification of risk for disease progres-
sion on ART individual variation of disease progression
within CD4 cell count strata is large [9]. TLCs have been
shown to be comparable predictors of mortality for HIV-
infected populations receiving [21] and not receiving
ART[22].
Thus, while TLCs may not correlate perfectly with CD4
cell counts, they may be as useful in predicting disease
progression and therefore can be equally useful in deter-
mining when ART should be initiated. While evaluating
how well ART-eligibility criteria based on TLCs perform in
comparison to CD4 cell count – based criteria can only be
answered by conducting clinical trials, this study has again
demonstrated that TLCs are useful proxy measures for
CD4 cell counts in determining ART eligibility.
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